Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07111832 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

StatusRecruiting
PhasePhase 3
Started2025-08-20
View on ClinicalTrials.gov ↗

Amendment history

2025-12-17
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-09→confirmed 2025-08-20
Study sitesdetails revised at 2 of 2 sites
2025-08-01
Original filing
This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).
Trial Details
NCT Number NCT07111832
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Enrollment 400 participants
Start Date 2025-08-20
Primary Completion 2028-03 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-18